Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases

被引：83

作者：

Beuselinck, B. ^{[1
,2
]}

Wolter, P. ^{[1
]}

Karadimou, A. ^{[2
]}

Elaidi, R. ^{[3
]}

Dumez, H. ^{[1
]}

Rogiers, A. ^{[1
]}

Van Cann, T. ^{[1
]}

Willems, L. ^{[4
]}

Body, J-J ^{[5
]}

Berkers, J. ^{[6
]}

Van Poppel, H. ^{[6
]}

Lerut, E. ^{[7
]}

Debruyne, P. ^{[8
]}

Paridaens, R. ^{[1
]}

Schoffski, P. ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Leuven Canc Inst, Univ Hosp Leuven, Dept Gen Med Oncol, B-3000 Louvain, Belgium

[2] Univ Paris 05, INSERM, Genom Fonct Tumeurs Solides U674, F-75015 Paris, France

[3] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Dept Med Oncol, F-75015 Paris, France

[4] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Pharm, B-3000 Louvain, Belgium

[5] Univ Libre Bruxelles, CHU Brugmann, Dept Med, B-1020 Brussels, Belgium

[6] Katholieke Univ Leuven, Dept Urol, Univ Hosp Leuven, B-3000 Louvain, Belgium

[7] Katholieke Univ Leuven, Dept Pathol, Univ Hosp Leuven, B-3000 Louvain, Belgium

[8] AZ Groeninge, Dept Med Oncol, B-8500 Kortrijk, Belgium

来源：

BRITISH JOURNAL OF CANCER | 2012年 / 107卷 / 10期

关键词：

bisphosphonates; bone metastases; renal cell carcinoma; osteonecrosis of the jaw; outcome; targeted therapy; ZOLEDRONIC ACID; DOUBLE-BLIND; PHASE-III; CANCER STATISTICS; INTERFERON-ALPHA; PROGRESSION-FREE; LUNG-CANCER; SURVIVAL; OSTEONECROSIS; SUNITINIB;

D O I：

10.1038/bjc.2012.385

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement. Concomitant bisphosphonates could probably improve outcomes but also induce osteonecrosis of the jaw (ONJ). METHODS: Retrospective study on all the renal cell carcinoma patients with bone metastases treated with sunitinib or sorafenib between November 2005 and June 2012 at the University Hospitals Leuven and AZ Groeninge in Kortrijk. RESULTS: Seventy-six patients were included in the outcome analysis: 49 treated with concomitant bisphosphonates, 27 with TKI alone. Both groups were well balanced in terms of prognostic and predictive markers. Response rate (38% vs 16% partial responses, P = 0.028), median progression-free survival (7.0 vs 4.0 months, P = 0.0011) and median overall survival (17.0 vs 7.0 months, P = 0.022) were significantly better in patients receiving bisphosphonates. The incidence of ONJ was 10% in patients treated with TKI and bisphosphonates. CONCLUSION: Concomitant use of bisphosphonates and TKI in renal cell carcinoma patients with bone involvement probably improves treatment efficacy, to be confirmed by prospective studies, but is associated with a high incidence of ONJ. British Journal of Cancer (2012) 107, 1665-1671. doi:10.1038/bjc.2012.385 www.bjcancer.com (C) 2012 Cancer Research UK

引用

页码：1665 / 1671

页数：7

共 29 条

[1] Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? [J].

Ayllon, J. ;

Launay-Vacher, V. ;

Medioni, J. ;

Cros, C. ;

Spano, J. P. ;

Oudard, S. .

ANNALS OF ONCOLOGY, 2009, 20 (03) :600-601

[2] Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].

Bamias, A ;

Kastritis, E ;

Bamia, C ;

Moulopoulos, LA ;

Melakopoulos, L ;

Bozas, G ;

Koutsoukou, V ;

Gika, D ;

Anagnostopoulos, A ;

Papadimitriou, C ;

Terpos, E ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587

[3] Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib [J].

Beuselinck, B. ;

Oudard, S. ;

Rixe, O. ;

Wolter, P. ;

Blesius, A. ;

Ayllon, J. ;

Elaidi, R. ;

Schoeffski, P. ;

Barrascout, E. ;

Morel, A. ;

Escudier, B. ;

Lang, H. ;

Zucman-Rossi, J. ;

Medioni, J. .

ANNALS OF ONCOLOGY, 2011, 22 (04) :794-800

[4] Osteonecrosis of the jaw in patients treated with sunitinib and zoledronic acid. [J].

Bozas, G. ;

Allgar, V. ;

Greenwood, G. ;

Maraveyas, A. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[5] Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently than Bisphosphonates Alone [J].

Christodoulou, C. ;

Pervena, A. ;

Klouvas, G. ;

Galani, E. ;

Falagas, M. E. ;

Tsakalos, G. ;

Visvikis, A. ;

Nikolakopoulou, A. ;

Acholos, V. ;

Karapanagiotidis, G. ;

Batziou, E. ;

Skarlos, D. V. .

ONCOLOGY, 2009, 76 (03) :209-211

[6] Bone metastasis: pathogenesis and therapeutic implications [J].

Clezardin, Philippe ;

Teti, Anna .

CLINICAL & EXPERIMENTAL METASTASIS, 2007, 24 (08) :599-608

[7] Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial [J].

Escudier, Bernard ;

Pluzanska, Anna ;

Koralewski, Piotr ;

Ravaud, Alain ;

Bracarda, Sergio ;

Szczylik, Cezary ;

Chevreau, Christine ;

Filipek, Marek ;

Melichar, Bohuslav ;

Bajetta, Emilio ;

Gorbunova, Vera ;

Bay, Jacques-Olivier ;

Bodrogi, Istvan ;

Jagiello-Gruszfeld, Agnieszka ;

Moore, Nicola .

LANCET, 2007, 370 (9605) :2103-2111

[8] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[9] Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer [J].

Guarneri, Valentina ;

Miles, David ;

Robert, Nicholas ;

Dieras, Veronique ;

Glaspy, John ;

Smith, Ian ;

Thomssen, Christoph ;

Biganzoli, Laura ;

Taran, Tanya ;

Conte, PierFranco .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (01) :181-188

[10] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

← 1 2 3 →